Prosecution Insights
Last updated: November 04, 2026
Application No. 18/740,140

SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS

Non-Final OA §112
Filed
Jun 11, 2024
Priority
Jun 13, 2023 — provisional 63/507,895
Examiner
VALLE, ERNESTO
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kovina Therapeutics Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
1y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
28 granted / 41 resolved
+8.3% vs TC avg
Strong +31% interview lift
Without
With
+30.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
34 currently pending
Career history
95
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
41.4%
+1.4% vs TC avg
§102
18.3%
-21.7% vs TC avg
§112
28.6%
-11.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 41 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application claims the benefit under 35 USC§ 119(e) of U.S. Provisional Patent Application No. 63/507,895 filed on June 13, 2023. Information Disclosure Statement The information disclosure statements (IDS) submitted on 09/04/2024, 10/30/2024, and 08/07/2025 were filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-18 in the reply filed on 09/25/2026 is acknowledged. Claims 1-2, 4-10, 13-18, and 21-23 are allowable. Claims 19-20, previously withdrawn from consideration as a result of a restriction requirement, require all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement between inventions I and II, as set forth in the Office action mailed on 07/29/2026, is hereby withdrawn and claims 19-20 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Status of the Application Claims 1-2, 4-10, and 13-23 are pending and under examination. Claims 1-2, 4-6, 8, and 13-20 have been amended. New claims 21-23 have been added. Claims 3, and 11-12 have been canceled by applicant without prejudice or disclaimer. Specification Drawings The drawings are objected to under 37 CFR 1.83(a) because they fail to show clearly defined compound functional groups as described in the specification [0103]. Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. PNG media_image1.png 125 705 media_image1.png Greyscale The drawings are not of sufficient quality to permit examination. Accordingly, replacement drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to this Office action. The replacement sheet(s) should be labeled “Replacement Sheet” in the page header (as per 37 CFR 1.84(c)) so as not to obstruct any portion of the drawing figures. If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. Applicant is given a shortened statutory period of TWO (2) MONTHS to submit new drawings in compliance with 37 CFR 1.81. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a) but in no case can any extension carry the date for reply to this letter beyond the maximum period of SIX MONTHS set by statute (35 U.S.C. 133). Failure to timely submit replacement drawing sheets will result in ABANDONMENT of the application. In particular, drawings dated 06/11/2024, Figs. 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 8A and 8B display values that are illegible. PNG media_image2.png 494 922 media_image2.png Greyscale PNG media_image3.png 465 935 media_image3.png Greyscale PNG media_image4.png 480 979 media_image4.png Greyscale PNG media_image5.png 454 974 media_image5.png Greyscale PNG media_image6.png 488 877 media_image6.png Greyscale PNG media_image7.png 453 877 media_image7.png Greyscale PNG media_image8.png 473 850 media_image8.png Greyscale PNG media_image9.png 444 878 media_image9.png Greyscale PNG media_image10.png 486 877 media_image10.png Greyscale PNG media_image11.png 447 872 media_image11.png Greyscale Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and 5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “other ” in claim 1 and claim 5 last lines is a relative term which renders the claim indefinite. The term “other” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. A skilled artisan would be unable to determine applicants intended substituents for R38 in claim 1 and R40 in claim 5 as the claims are currently written. This rejection may be overcome by amending claim language to clearly which substituents applicants intend. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: Claims 2, 4, 6-10 and 13-23 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claims 1 and 5 are rejected, claims 2, 4, 6-10, and 13-23 are objected to. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERNESTO VALLE JR whose telephone number is (703)756-5356. The examiner can normally be reached 0730-1700 M-F EST, 1st Friday off. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam C Milligan can be reached at 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /E.V./Examiner, Art Unit 1623 /SAMANTHA L SHTERENGARTS/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Jun 11, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773409
TREATMENT OF EOSINOPHILIC DISORDERS WITH AVAPRITINIB
4y 7m to grant Granted Oct 27, 2026
Patent 12740985
SMALL MOLECULE LIVER X RECEPTOR MODULATORS AND USES THEREOF
4y 7m to grant Granted Sep 22, 2026
Patent 12734170
CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
2y 8m to grant Granted Sep 15, 2026
Patent 12673914
CONTINUOUS PROCESS FOR THE SYNTHESIS OF DIMETHYL CARBONATE OVER A CERIUM-BASED CATALYST FORMULATION
2y 11m to grant Granted Jul 07, 2026
Patent 12662460
COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE
3y 12m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+30.9%)
3y 5m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 41 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month